Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.58 |
| ▸ | KDR | P35968 | 14/20 | 0.58 |
| ▸ | SRC | P12931 | 14/20 | 0.58 |
| ▸ | PIK3CD | O00329 | 13/20 | 0.58 |
| ▸ | PIK3CA | P42336 | 13/20 | 0.58 |
| ▸ | PIK3CB | P42338 | 13/20 | 0.58 |
| ▸ | PIK3CG | P48736 | 13/20 | 0.58 |
| ▸ | PRKDC | P78527 | 13/20 | 0.58 |
| ▸ | ABL1 | P00519 | 12/20 | 0.58 |
| ▸ | HCK | P08631 | 12/20 | 0.58 |
| ▸ | MTOR | P42345 | 12/20 | 0.58 |
| ▸ | EPHB4 | P54760 | 12/20 | 0.58 |
| ▸ | PI4KB | Q9UBF8 | 7/20 | 0.57 |
| ▸ | RET | P07949 | 1/20 | 0.53 |
| ▸ | BTK | Q06187 | 3/20 | 0.53 |
| ▸ | LCK | P06239 | 3/20 | 0.53 |
| ▸ | LYN | P07948 | 1/20 | 0.53 |
| ▸ | NUDT14 | O95848 | 1/20 | 0.52 |
| ▸ | NUDT5 | Q9UKK9 | 1/20 | 0.52 |
| ▸ | TEK | Q02763 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15613465 | 0.85 | PIK3CD (0.72) | EGFRKDRSRCPIK3CDPIK3CA | |
| SCHEMBL29441895 | 0.85 | BTK (0.76) | EGFRKDRSRCABL1HCK | |
| SCHEMBL22243245 | 0.85 | BTK (0.76) | EGFRKDRSRCABL1HCK | |
| SCHEMBL24041260 | 0.85 | BTK (0.76) | EGFRKDRSRCABL1HCK | |
| SCHEMBL22243246 | 0.85 | BTK (0.76) | EGFRKDRSRCABL1HCK | |
| SCHEMBL22243264 | 0.84 | BTK (0.63) | EGFRKDRSRCPIK3CDPIK3CA | |
| SCHEMBL22230580 | 0.84 | BTK (0.63) | EGFRKDRSRCPIK3CDPIK3CA | |
| SCHEMBL22243263 | 0.84 | BTK (0.63) | EGFRKDRSRCPIK3CDPIK3CA | |
| SCHEMBL15613506 | 0.82 | PIK3CD (0.59) | EGFRKDRSRCPIK3CDPIK3CA | |
| SCHEMBL22243326 | 0.79 | BTK (0.71) | EGFRKDRSRCABL1HCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4116303-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER | Loxo Oncology, Inc. (US) | 2023-01-11 | — | — | EP | disclosed |
| EP-3350184-B1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER | LOXO ONCOLOGY INC (US) | 2022-10-19 | — | — | EP | disclosed |
| CN-114685516-A | Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer | 洛克索肿瘤学股份有限公司 | 2022-07-01 | — | — | CN | disclosed |
| CN-108431007-B | Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer | 洛克索肿瘤学股份有限公司 | 2022-06-07 | — | — | CN | disclosed |
| US-10611766-B2 | Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer | LOXO ONCOLOGY INC. (US) | 2020-04-07 | — | — | US | disclosed |
| US-10399989-B2 | Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer | LOXO ONCOLOGY, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-10399990-B2 | Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer | LOXO ONCOLOGY, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180362533-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER | REDX PHARMA PLC. (GB) | 2018-12-20 | — | — | US | disclosed |
| US-20180362537-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER | REDX PHARMA PLC (GB) | 2018-12-20 | — | — | US | disclosed |
| US-20180298008-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER | REDX PHARMA PLC (GB) | 2018-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10611766-B2 | Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer | BTK, SYK, LCK | EGFR 740/4885KDR 1370/4885SRC 20/4885 |
| US-10399990-B2 | Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer | BTK, SYK, LCK | EGFR 740/4885KDR 1370/4885SRC 20/4885 |
| US-10399989-B2 | Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer | BTK, SYK, LCK | EGFR 740/4885KDR 1370/4885SRC 20/4885 |
| US-20180362537-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER | BTK, SYK, LCK | EGFR 740/4885KDR 1370/4885SRC 20/4885 |
| US-20180298008-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER | BTK, SYK, LCK | EGFR 740/4885KDR 1370/4885SRC 20/4885 |
| US-20180362533-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER | BTK, SYK, LCK | EGFR 740/4885KDR 1370/4885SRC 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.